Funding from the Anthem-backed series E round will support the commercialisation of Sera's biomarker tests, which predict the chances of preterm births.

Sera Prognostics, a US-based provider of biomarker tests for pregnant women, closed a $100m series E round co-led by health benefits provider Anthem and investment firm Blue Ox Healthcare Partners yesterday. The round included Vivo Capital, aMoon Fund, Parian Global Management and undisclosed additional backers, and it increased the company‚Äôs overall funding to $220m. Founded…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.